Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis
<h3>Background</h3><p dir="ltr"><u>Chronic obstructive pulmonary disease </u>(COPD) significantly impacts global health due to persistent airflow limitation and inflammation. Despite standard therapies, symptoms persist. Ensifentrine, targeting both <u>b...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513539573547008 |
|---|---|
| author | Ambanna Yappalparvi (21260018) |
| author2 | Ashok Kumar Balaraman (22282333) G. Padmapriya (22282336) Shilpa Gaidhane (745829) Irwanjot Kaur (20767955) Madan Lal (773504) Suhaib Iqbal (20767958) G.V. Siva Prasad (22282339) Atreyi Pramanik (8334333) Teena Vishwakarma (20767964) Praveen Malik (6560504) Promila Sharma (14322356) Ankit Punia (20767967) Megha Jagga (20767970) Doddolla Lingamaiah (22282342) Rachana Mehta (12059853) Sanjit Sah (19709571) Quazi Syed Zahiruddin (13231791) Hashem Abu Serhan (16003271) Muhammed Shabil (16677981) Ganesh Bushi (19709574) |
| author2_role | author author author author author author author author author author author author author author author author author author author author |
| author_facet | Ambanna Yappalparvi (21260018) Ashok Kumar Balaraman (22282333) G. Padmapriya (22282336) Shilpa Gaidhane (745829) Irwanjot Kaur (20767955) Madan Lal (773504) Suhaib Iqbal (20767958) G.V. Siva Prasad (22282339) Atreyi Pramanik (8334333) Teena Vishwakarma (20767964) Praveen Malik (6560504) Promila Sharma (14322356) Ankit Punia (20767967) Megha Jagga (20767970) Doddolla Lingamaiah (22282342) Rachana Mehta (12059853) Sanjit Sah (19709571) Quazi Syed Zahiruddin (13231791) Hashem Abu Serhan (16003271) Muhammed Shabil (16677981) Ganesh Bushi (19709574) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ambanna Yappalparvi (21260018) Ashok Kumar Balaraman (22282333) G. Padmapriya (22282336) Shilpa Gaidhane (745829) Irwanjot Kaur (20767955) Madan Lal (773504) Suhaib Iqbal (20767958) G.V. Siva Prasad (22282339) Atreyi Pramanik (8334333) Teena Vishwakarma (20767964) Praveen Malik (6560504) Promila Sharma (14322356) Ankit Punia (20767967) Megha Jagga (20767970) Doddolla Lingamaiah (22282342) Rachana Mehta (12059853) Sanjit Sah (19709571) Quazi Syed Zahiruddin (13231791) Hashem Abu Serhan (16003271) Muhammed Shabil (16677981) Ganesh Bushi (19709574) |
| dc.date.none.fl_str_mv | 2024-12-09T12:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.rmed.2024.107863 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Safety_and_efficacy_of_ensifentrine_in_COPD_A_systemic_review_and_meta-analysis/30172996 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Ensifentrine COPD PDE3 inhibitor PDE4 inhibitor Dyspnea FEV1 Quality of life Adverse events |
| dc.title.none.fl_str_mv | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr"><u>Chronic obstructive pulmonary disease </u>(COPD) significantly impacts global health due to persistent airflow limitation and inflammation. Despite standard therapies, symptoms persist. Ensifentrine, targeting both <u>bronchoconstriction</u> and inflammation as a dual phosphodiesterase 3 and 4 inhibitor, offers a promising therapeutic advancement for COPD management. This meta-analysis evaluates the safety and efficacy of ensifentrine in improving lung function, dyspnea, and quality of life in COPD patients. </p><h3>Methods</h3><p dir="ltr">We searched PubMed, Embase, and Web of Science through August 2024 for <u>randomized controlled trials</u> evaluating ensifentrine in COPD patients over a minimum of four weeks. Data extraction and screening utilized Knowledge software, and meta-analyses were performed using R v4.4 with a random-effects model. </p><h3>Results</h3><p dir="ltr">From 206 studies identified, four met our inclusion criteria. Ensifentrine improved FEV1 significantly at a dose of 3 mg (LS mean difference: 40.90 mL; 95 % CI: 19.65–62.15). It also improved dyspnea as measured by the Transition Dyspnea Index (TDI) (LS mean difference: 0.91; 95 % CI: 0.61–1.21) and quality of life according to the St. George's Respiratory Questionnaire-C (SGRQ-C) scores (LS mean difference: −1.92; 95 % CI: −3.28 to −0.55). Safety profiles were comparable between the ensifentrine and placebo groups, with no significant increase in treatment-emergent <u>adverse events</u> (TEAEs) (RR: 1.02; 95 % CI: 0.94–1.10). </p><h3>Conclusion</h3><p dir="ltr">Ensifentrine significantly enhances lung function, reduces dyspnea, and improves quality of life in COPD patients, especially at a 3mg dose. These benefits, coupled with a stable safety profile, support its use as an adjunctive therapy in COPD management.</p><h2>Other Information</h2><p dir="ltr">Published in: Respiratory Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.rmed.2024.107863" target="_blank">https://dx.doi.org/10.1016/j.rmed.2024.107863</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_0f4d143b1b7de6bdbb24d02b832b860a |
| identifier_str_mv | 10.1016/j.rmed.2024.107863 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30172996 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysisAmbanna Yappalparvi (21260018)Ashok Kumar Balaraman (22282333)G. Padmapriya (22282336)Shilpa Gaidhane (745829)Irwanjot Kaur (20767955)Madan Lal (773504)Suhaib Iqbal (20767958)G.V. Siva Prasad (22282339)Atreyi Pramanik (8334333)Teena Vishwakarma (20767964)Praveen Malik (6560504)Promila Sharma (14322356)Ankit Punia (20767967)Megha Jagga (20767970)Doddolla Lingamaiah (22282342)Rachana Mehta (12059853)Sanjit Sah (19709571)Quazi Syed Zahiruddin (13231791)Hashem Abu Serhan (16003271)Muhammed Shabil (16677981)Ganesh Bushi (19709574)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical sciencesHealth sciencesEpidemiologyEnsifentrineCOPDPDE3 inhibitorPDE4 inhibitorDyspneaFEV1Quality of lifeAdverse events<h3>Background</h3><p dir="ltr"><u>Chronic obstructive pulmonary disease </u>(COPD) significantly impacts global health due to persistent airflow limitation and inflammation. Despite standard therapies, symptoms persist. Ensifentrine, targeting both <u>bronchoconstriction</u> and inflammation as a dual phosphodiesterase 3 and 4 inhibitor, offers a promising therapeutic advancement for COPD management. This meta-analysis evaluates the safety and efficacy of ensifentrine in improving lung function, dyspnea, and quality of life in COPD patients. </p><h3>Methods</h3><p dir="ltr">We searched PubMed, Embase, and Web of Science through August 2024 for <u>randomized controlled trials</u> evaluating ensifentrine in COPD patients over a minimum of four weeks. Data extraction and screening utilized Knowledge software, and meta-analyses were performed using R v4.4 with a random-effects model. </p><h3>Results</h3><p dir="ltr">From 206 studies identified, four met our inclusion criteria. Ensifentrine improved FEV1 significantly at a dose of 3 mg (LS mean difference: 40.90 mL; 95 % CI: 19.65–62.15). It also improved dyspnea as measured by the Transition Dyspnea Index (TDI) (LS mean difference: 0.91; 95 % CI: 0.61–1.21) and quality of life according to the St. George's Respiratory Questionnaire-C (SGRQ-C) scores (LS mean difference: −1.92; 95 % CI: −3.28 to −0.55). Safety profiles were comparable between the ensifentrine and placebo groups, with no significant increase in treatment-emergent <u>adverse events</u> (TEAEs) (RR: 1.02; 95 % CI: 0.94–1.10). </p><h3>Conclusion</h3><p dir="ltr">Ensifentrine significantly enhances lung function, reduces dyspnea, and improves quality of life in COPD patients, especially at a 3mg dose. These benefits, coupled with a stable safety profile, support its use as an adjunctive therapy in COPD management.</p><h2>Other Information</h2><p dir="ltr">Published in: Respiratory Medicine<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.rmed.2024.107863" target="_blank">https://dx.doi.org/10.1016/j.rmed.2024.107863</a></p>2024-12-09T12:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.rmed.2024.107863https://figshare.com/articles/journal_contribution/Safety_and_efficacy_of_ensifentrine_in_COPD_A_systemic_review_and_meta-analysis/30172996CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301729962024-12-09T12:00:00Z |
| spellingShingle | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis Ambanna Yappalparvi (21260018) Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Ensifentrine COPD PDE3 inhibitor PDE4 inhibitor Dyspnea FEV1 Quality of life Adverse events |
| status_str | publishedVersion |
| title | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| title_full | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| title_fullStr | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| title_full_unstemmed | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| title_short | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| title_sort | Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis |
| topic | Biomedical and clinical sciences Clinical sciences Pharmacology and pharmaceutical sciences Health sciences Epidemiology Ensifentrine COPD PDE3 inhibitor PDE4 inhibitor Dyspnea FEV1 Quality of life Adverse events |